Australia's TGA designates new orphan drug
This article was originally published in Scrip
Executive Summary
Australia's Therapeutic Goods Administration (TGA) has given Roche'smonoclonal antibody, Avastin (bevacizumab), orphan drug status for malignant glioma. The product is available in 100mg (4mLs) and 400mg (16mLs) single-dose vials. It received designated status on January 13th.